DeepMed Research

The Case Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1826-01-01

Employees: 5K

Market Cap: -

Website: http://www.case.edu/cancer

Clinical Trials

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Phase 4

Completed

Conditions: Kidney Cancer

First Posted Date: 2003-06-02

Last Posted Date: 2014-01-09

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT00006864

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Northwestern Connecticut Oncology-Hematology Associates, Torrington, Connecticut, United States

Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: brostallicin

First Posted Date: 2003-05-07

Last Posted Date: 2014-01-16

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 3

Registration Number: NCT00060203

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2003-05-07

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 26

Registration Number: NCT00060242

Locations: 🇺🇸
Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

GW786034 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-05-07

Last Posted Date: 2013-09-20

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT00060151

Locations: 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-03-07

Last Posted Date: 2010-06-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 9

Registration Number: NCT00055640

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

Interventions: Drug: cyclophosphamide
Drug: busulfan
Radiation: radiation therapy
Drug: cytarabine
Drug: Etoposide
Procedure: Stem Cell Transfusion

First Posted Date: 2003-02-06

Last Posted Date: 2013-07-24

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 34

Registration Number: NCT00054327

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-02-06

Last Posted Date: 2020-07-27

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 2

Registration Number: NCT00054301

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Phase 1

Completed

Conditions: Leukemia
Multiple Myeloma and Plasma Cell Neoplasm
Lymphoma
Chronic Myeloproliferative Disorders
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

Interventions: Biological: anti-thymocyte globulin
Biological: filgrastim
Drug: cyclophosphamide
Drug: fludarabine phosphate
Procedure: umbilical cord blood transplantation
Drug: methylprednisolone

First Posted Date: 2003-02-06

Last Posted Date: 2020-07-27

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 55

Registration Number: NCT00054236

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

Phase 2

Completed

Conditions: Myelodysplastic/Myeloproliferative Diseases
Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-01-28

Last Posted Date: 2010-06-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 42

Registration Number: NCT00053287

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2003-01-28

Last Posted Date: 2010-06-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT00053300

Locations: 🇺🇸
Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy